EUCTR2017-003466-28-ES进行中（未招募）1 期
A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Has pathologically documented unresectable, recurrent, or metastatic
- •colorectal adenocarcinoma (until sponsor's notification to the study
- •sites, subject must be a RAS/BRAF wild-type cancer)
- •- Has received at least 2 prior regimens of standard treatment
- •- Has measurable disease assessed by the investigator based on RECIST
- •version 1.1.
- •- Has an Eastern Cooperative Oncology Group Performance Status (ECOGPS) of 0 to 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Has a medical history of myocardial infarction within 6 months, symptomatic congestive heart failure
- •- Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- •- Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancerHuman epidermal growth factor receptor 2 (HER2)- expressing advanced colorectal cancerMedDRA version: 20.0 Level: LLT Classification code 10010029 Term: Colorectal cancer NOS System Organ Class: 100000004864EUCTR2017-003466-28-GBDaiichi Sankyo Inc.90
进行中（未招募）
1 期
A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancerEUCTR2017-003466-28-ITDAIICHI SANKYO INC.78
进行中（未招募）
1 期
A Phase 2 study of DS-8201a for HER2-Positive breast cancer that has either spread and/or cannot be treated with surgery and is resistant or non-responsive to T-DM1 treatment.EUCTR2016-004986-18-ESDaiichi Sankyo Inc.230
进行中（未招募）
1 期
A Phase 2 study of DS-8201a for HER2-Positive breast cancer that has either spread and/or cannot be treated with surgery and is resistant or non-responsive to T-DM1 treatment.nresectable/metastatic breast cancer with HER2 positive expressionMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2016-004986-18-ITDAIICHI SANKYO INC.253
进行中（未招募）
1 期
A Phase 2 study of DS-8201a for HER2-Positive breast cancer that has either spread and/or cannot be treated with surgery and is resistant or non-responsive to T-DM1 treatment.EUCTR2016-004986-18-FRDaiichi Sankyo Inc.253